TY - JOUR
T1 - Retinoids
T2 - Therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma
AU - Zhang, Chunlei
AU - Duvic, Madeleine
PY - 2003
Y1 - 2003
N2 - Retinoids, natural and synthetic derivatives of vitamin A, are biological regulators of differentiation, proliferation, apoptosis, and immune response. Retinoic-acid-receptor-selective retinoids (all-trans retinoic acid, 13-cis-retinoic acid, and the synthetic analogs isotretinoin, etretinate and acitretin) have been used for years as monotherapy and/or in combination for treatment of cutaneous T-cell lymphoma (CTCL). Orally administered bexarotene, the first synthetic highly selective retinoid-X-receptor retinoid to be approved by the FDA for CTCL, was shown to be active against the cutaneous manifestations of all stages of CTCL. The topical gel formulation was also effective for early cutaneous manifestations of CTCL or as an adjunct to systemic or phototherapy. Bexarotene treatment induces apoptosis of CTCL cells with down-regulation of its receptors and of survivin, an inhibitor of apoptosis. Identification of new receptor subtype-selective retinoids, combination of various receptor-selective retinoids or other agents, and a new drug delivery system may improve the clinical efficacy of retinoids in the future.
AB - Retinoids, natural and synthetic derivatives of vitamin A, are biological regulators of differentiation, proliferation, apoptosis, and immune response. Retinoic-acid-receptor-selective retinoids (all-trans retinoic acid, 13-cis-retinoic acid, and the synthetic analogs isotretinoin, etretinate and acitretin) have been used for years as monotherapy and/or in combination for treatment of cutaneous T-cell lymphoma (CTCL). Orally administered bexarotene, the first synthetic highly selective retinoid-X-receptor retinoid to be approved by the FDA for CTCL, was shown to be active against the cutaneous manifestations of all stages of CTCL. The topical gel formulation was also effective for early cutaneous manifestations of CTCL or as an adjunct to systemic or phototherapy. Bexarotene treatment induces apoptosis of CTCL cells with down-regulation of its receptors and of survivin, an inhibitor of apoptosis. Identification of new receptor subtype-selective retinoids, combination of various receptor-selective retinoids or other agents, and a new drug delivery system may improve the clinical efficacy of retinoids in the future.
KW - Bexarotene
KW - Mycosis fungoides
KW - Retinoid receptors
KW - Sézary syndrome
UR - http://www.scopus.com/inward/record.url?scp=0346099399&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0346099399&partnerID=8YFLogxK
U2 - 10.1111/j.1396-0296.2003.01644.x
DO - 10.1111/j.1396-0296.2003.01644.x
M3 - Review article
C2 - 14686975
AN - SCOPUS:0346099399
SN - 1396-0296
VL - 16
SP - 322
EP - 330
JO - Dermatologic Therapy
JF - Dermatologic Therapy
IS - 4
ER -